These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 20585031

  • 1. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae.
    Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Oishi K, Hollingshead SK, Briles DE, Fujihashi K.
    J Immunol; 2010 Aug 01; 185(3):1755-62. PubMed ID: 20585031
    [Abstract] [Full Text] [Related]

  • 2. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.
    Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Hollingshead SK, Briles DE, Fujihashi K.
    J Immunol; 2011 Feb 15; 186(4):2454-61. PubMed ID: 21242514
    [Abstract] [Full Text] [Related]

  • 3. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
    Yamamoto M, Briles DE, Yamamoto S, Ohmura M, Kiyono H, McGhee JR.
    J Immunol; 1998 Oct 15; 161(8):4115-21. PubMed ID: 9780183
    [Abstract] [Full Text] [Related]

  • 4. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
    Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K.
    Infect Immun; 2011 Jul 15; 79(7):2819-28. PubMed ID: 21536790
    [Abstract] [Full Text] [Related]

  • 5. Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination.
    Baatarjav T, Kataoka K, Gilbert RS, Terao Y, Fukui M, Goto M, Kawabata S, Yamamoto M, Fujihashi K, Ito HO.
    Vaccine; 2011 Aug 05; 29(34):5747-57. PubMed ID: 21683111
    [Abstract] [Full Text] [Related]

  • 6. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.
    Oma K, Zhao J, Ezoe H, Akeda Y, Koyama S, Ishii KJ, Kataoka K, Oishi K.
    Vaccine; 2009 May 21; 27(24):3181-8. PubMed ID: 19446189
    [Abstract] [Full Text] [Related]

  • 7. Respiratory FimA-Specific Secretory IgA Antibodies Upregulated by DC-Targeting Nasal Double DNA Adjuvant Are Essential for Elimination of Porphyromonas gingivalis.
    Kataoka K, Kawabata S, Koyanagi K, Hashimoto Y, Miyake T, Fujihashi K.
    Front Immunol; 2021 May 21; 12():634923. PubMed ID: 33717178
    [Abstract] [Full Text] [Related]

  • 8. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant.
    Saito M, Otake S, Ohmura M, Hirasawa M, Takada K, Mega J, Takahashi I, Kiyono H, McGhee JR, Takeda Y, Yamamoto M.
    J Infect Dis; 2001 Mar 01; 183(5):823-6. PubMed ID: 11181162
    [Abstract] [Full Text] [Related]

  • 9. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage.
    Sun K, Johansen FE, Eckmann L, Metzger DW.
    J Immunol; 2004 Oct 01; 173(7):4576-81. PubMed ID: 15383591
    [Abstract] [Full Text] [Related]

  • 10. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice.
    Ezoe H, Akeda Y, Piao Z, Aoshi T, Koyama S, Tanimoto T, Ishii KJ, Oishi K.
    Vaccine; 2011 Feb 17; 29(9):1754-61. PubMed ID: 21219977
    [Abstract] [Full Text] [Related]

  • 11. IL-12 is an effective adjuvant for induction of mucosal immunity.
    Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR.
    J Immunol; 1999 Jan 01; 162(1):122-8. PubMed ID: 9886377
    [Abstract] [Full Text] [Related]

  • 12. A novel neurotoxoid vaccine prevents mucosal botulism.
    Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K.
    J Immunol; 2005 Feb 15; 174(4):2190-5. PubMed ID: 15699151
    [Abstract] [Full Text] [Related]

  • 13. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).
    Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN.
    Microb Pathog; 2010 Jun 15; 48(6):205-13. PubMed ID: 20206678
    [Abstract] [Full Text] [Related]

  • 14. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y.
    Int Immunopharmacol; 2018 Aug 15; 61():385-393. PubMed ID: 29945026
    [Abstract] [Full Text] [Related]

  • 15. A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx.
    Kodama S, Hirano T, Noda K, Abe N, Suzuki M.
    Vaccine; 2010 Mar 16; 28(13):2510-6. PubMed ID: 20117272
    [Abstract] [Full Text] [Related]

  • 16. Transcutaneous immunization with pneumococcal surface protein A in mice.
    Nagano H, Kawabata M, Sugita G, Tsuruhara A, Ohori J, Jimura T, Miyashita K, Kurono Y, Tomonaga K, Briles DE, Fujihashi K.
    Laryngoscope; 2018 Mar 16; 128(3):E91-E96. PubMed ID: 29226330
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K, Fukuyama Y, Briles DE, Miyake T, Fujihashi K.
    Microbiol Immunol; 2017 Jun 16; 61(6):195-205. PubMed ID: 28463465
    [Abstract] [Full Text] [Related]

  • 18. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
    Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS.
    J Infect Dis; 2000 Dec 16; 182(6):1694-701. PubMed ID: 11069242
    [Abstract] [Full Text] [Related]

  • 19. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.
    Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA.
    Vaccine; 2004 Sep 03; 22(25-26):3449-56. PubMed ID: 15308371
    [Abstract] [Full Text] [Related]

  • 20. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M, McDaniel LS, Kawabata K, Briles DE, Jackson RJ, McGhee JR, Kiyono H.
    Infect Immun; 1997 Feb 03; 65(2):640-4. PubMed ID: 9009325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.